RT Journal Article
SR Electronic
T1 Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1672
OP 1676
DO 10.2967/jnumed.121.262484
VO 62
IS 12
A1 Mark A. Sellmyer
A1 Iris K. Lee
A1 David A. Mankoff
YR 2021
UL http://jnm.snmjournals.org/content/62/12/1672.abstract
AB Precision medicine, in which the molecular underpinnings of the disease are assessed for tailored therapies, has greatly impacted cancer care. In parallel, a new pillar of therapeutics has emerged with profound success, including immunotherapies such as checkpoint inhibitors and cell-based therapies. Nonetheless, it remains essential to develop paradigms to predict and monitor for therapeutic response. Molecular imaging has the potential to add substantially to all phases of cancer patient care: predictive, companion diagnostics can illuminate therapeutic target density within a tumor, and pharmacodynamic imaging biomarkers can complement traditional modalities to judge a favorable treatment response. This “Focus on Molecular Imaging” article discusses the current role of molecular imaging in oncology and highlights an additional step in the clinical paradigm termed a therapeutic biomarker, which serves to assess whether next-generation drugs reach their target to elicit a favorable clinical response.